Summary
Boston Scientific Corporation (BSX) reported its third-quarter financial results for the period ending September 29, 2010. The filing indicates a focus on operational performance and financial stability during this period. Investors should note the company's continued efforts in managing its product portfolio and associated costs, which are critical for future profitability and growth. The company's financial statements and management's discussion provide insights into revenue streams, expense management, and the overall financial health, setting the context for the company's strategic direction in a competitive medical device market.
Financial Highlights
46 data pointsBeta
Financial Statements
Beta
| Revenue | $1.92B |
| Cost of Revenue | $623.00M |
| Gross Profit | $1.29B |
| SG&A Expenses | $634.00M |
| Operating Expenses | $1.04B |
| Operating Income | $251.00M |
| Interest Expense | $91.00M |
| Net Income | $190.00M |
| EPS (Basic) | $0.13 |
| EPS (Diluted) | $0.12 |
| Shares Outstanding (Basic) | 1.52B |
| Shares Outstanding (Diluted) | 1.53B |
Key Highlights
- 1The 10-Q filing covers the third quarter of 2010, providing a snapshot of the company's financial performance during that period.
- 2Key financial statements, including the Condensed Consolidated Statements of Operations, Balance Sheets, and Cash Flows, are included for investor review.
- 3Management's Discussion and Analysis (MD&A) offers insights into the company's financial condition, results of operations, and liquidity.
- 4The report details legal proceedings, which could have a material impact on the company's financial position.
- 5Risk factors are outlined, providing investors with an understanding of potential challenges and uncertainties facing the company.
- 6Exhibits are attached, which may contain important supporting documentation for the financial information presented.